Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $46.50.

A number of analysts have issued reports on the company. Canaccord Genuity Group assumed coverage on Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright raised their price target on Tyra Biosciences from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Barclays assumed coverage on Tyra Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Monday, April 20th. Finally, Jefferies Financial Group raised their price target on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, February 3rd.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the sale, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently modified their holdings of TYRA. Commodore Capital LP increased its position in Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter. Farallon Capital Management LLC lifted its position in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares in the last quarter. Caligan Partners LP grew its stake in Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after buying an additional 506,875 shares during the period. Boone Capital Management LLC purchased a new stake in Tyra Biosciences during the fourth quarter worth approximately $10,476,000. Finally, Elmind Capital LP acquired a new stake in shares of Tyra Biosciences in the fourth quarter worth $9,202,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $37.59 on Monday. The stock’s 50-day moving average price is $35.46 and its two-hundred day moving average price is $27.20. Tyra Biosciences has a 12-month low of $8.75 and a 12-month high of $40.65. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -18.70 and a beta of 0.96.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). As a group, research analysts forecast that Tyra Biosciences will post -2.42 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.